MA33904B1 - Utilisation d'un agent de modification d'hormones surrénaliennes - Google Patents

Utilisation d'un agent de modification d'hormones surrénaliennes

Info

Publication number
MA33904B1
MA33904B1 MA35039A MA35039A MA33904B1 MA 33904 B1 MA33904 B1 MA 33904B1 MA 35039 A MA35039 A MA 35039A MA 35039 A MA35039 A MA 35039A MA 33904 B1 MA33904 B1 MA 33904B1
Authority
MA
Morocco
Prior art keywords
change factor
adrenal hormone
hormone change
subject
adrenal
Prior art date
Application number
MA35039A
Other languages
Arabic (ar)
English (en)
Inventor
Qi-Ying Hu
Gary Ksander
Erik Meredith
Lauren G Monovich
Julien Papillon
Christoph Schumacher
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43735742&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33904(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA33904B1 publication Critical patent/MA33904B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503—Five-membered rings
    • C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne un procédé de traitement d'une maladie ou d'un trouble caractérisé par des taux accrus de l'hormone du stress et/ou des taux diminués d'hormones androgènes dans un sujet. Ce procédé comprend l'administration au sujet d'une quantité thérapeutiquement efficace d'un composé représenté par la formule (i) : dans laquelle n vaut 1 ou 3 ; r représente l'hydrogène ou c(o)n(r
MA35039A 2010-01-14 2011-01-13 Utilisation d'un agent de modification d'hormones surrénaliennes MA33904B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29498010P 2010-01-14 2010-01-14
PCT/US2011/021100 WO2011088188A1 (fr) 2010-01-14 2011-01-13 Utilisation d'un agent de modification d'hormones surrénaliennes

Publications (1)

Publication Number Publication Date
MA33904B1 true MA33904B1 (fr) 2013-01-02

Family

ID=43735742

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35039A MA33904B1 (fr) 2010-01-14 2011-01-13 Utilisation d'un agent de modification d'hormones surrénaliennes

Country Status (34)

Country Link
US (2) US8609862B2 (fr)
EP (2) EP3527208A1 (fr)
JP (4) JP5602250B2 (fr)
KR (1) KR101412206B1 (fr)
CN (2) CN102711916B (fr)
AU (1) AU2011205290C1 (fr)
BR (1) BR112012017458B1 (fr)
CA (1) CA2786443C (fr)
CL (1) CL2012001961A1 (fr)
CY (2) CY1121320T1 (fr)
DK (1) DK2523731T3 (fr)
ES (1) ES2707596T3 (fr)
HR (1) HRP20190064T1 (fr)
HU (2) HUE041967T2 (fr)
IL (1) IL220804A0 (fr)
LT (2) LT2523731T (fr)
LU (1) LUC00159I2 (fr)
MA (1) MA33904B1 (fr)
ME (1) ME03371B (fr)
MX (2) MX2012008212A (fr)
NL (1) NL301043I2 (fr)
NO (1) NO2020012I1 (fr)
NZ (1) NZ601077A (fr)
PH (1) PH12012501422B1 (fr)
PL (1) PL2523731T3 (fr)
PT (1) PT2523731T (fr)
RS (1) RS58234B1 (fr)
RU (1) RU2598708C2 (fr)
SG (1) SG182393A1 (fr)
SI (1) SI2523731T1 (fr)
TN (1) TN2012000352A1 (fr)
TR (1) TR201900515T4 (fr)
WO (1) WO2011088188A1 (fr)
ZA (1) ZA201205058B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA33904B1 (fr) * 2010-01-14 2013-01-02 Novartis Ag Utilisation d'un agent de modification d'hormones surrénaliennes
RU2674259C2 (ru) 2010-06-16 2018-12-06 Эмбера Ньюротерапьютикс, Инк Композиции и способы лечения зависимости, психических расстройств и нейродегенеративного заболевания
AR086665A1 (es) 2011-06-14 2014-01-15 Lilly Co Eli Inhibidor de aldosterona sintasa y composiciones farmaceuticas
WO2013043520A1 (fr) 2011-09-22 2013-03-28 Merck Sharp & Dohme Corp. Composés triazolopyridyle à utiliser en tant qu'inhibiteurs de l'aldostérone synthase
US9351973B2 (en) 2011-09-22 2016-05-31 Merck Sharp & Dohme Corp. Pyrazolopyridyl compounds as aldosterone synthase inhibitors
EP2757882B1 (fr) 2011-09-22 2020-11-04 Merck Sharp & Dohme Corp. Composés imidazopyridyliques utilisables en tant qu'inhibiteurs de l'aldostérone synthase
HRP20160178T1 (hr) 2012-01-17 2016-03-25 Novartis Ag Novi oblici i soli dihidropirolo[1,2-c]imidazolil inhibitora aldosteron sintaze ili aromataze
WO2013153129A1 (fr) * 2012-04-12 2013-10-17 Novartis Ag Combinaison d'analogues de la somatostatine et d'inhibiteurs de la 11-bêta-hydroxylase
CA2886117C (fr) 2012-10-05 2022-05-31 Merck Sharp & Dohme Corp. Composes d'indoline utilises comme inhibiteurs de l'aldosterone synthase
JP2015093832A (ja) * 2013-11-08 2015-05-18 日本メジフィジックス株式会社 放射性ハロゲン標識化合物又はその塩、これを含む医薬
HRP20181406T1 (hr) * 2014-07-07 2018-10-19 Novartis Ag Farmaceutski dozni oblici
WO2016048984A1 (fr) * 2014-09-25 2016-03-31 Cortendo Ab (Publ) Méthodes et compositions pour le traitement du syndrome de cushing basées sur le 2s,4r kétoconazole
CN107207518B (zh) 2015-01-29 2021-03-30 雷科尔达蒂股份公司 生产稠合咪唑衍生物的工艺
WO2016164476A2 (fr) 2015-04-06 2016-10-13 Millendo Therapeutics, Inc. Polythérapie pour le traitement de troubles liés à un excès de production de cortisol
CN108025008A (zh) * 2015-06-22 2018-05-11 安比拉神经疗法公司 用于治疗物质使用障碍、成瘾和精神病的组合物和方法
EP3592350B1 (fr) 2017-03-10 2025-03-05 Embera NeuroTherapeutics, Inc. Compositions pharmaceutiques comprenant métyrapone et oxazepam et leurs utilisations

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4889861A (en) * 1982-12-21 1989-12-26 Ciba-Geigy Corp. Substituted imidazo[1,5-a]pyridine derivatives and other substituted bicyclic derivatives and their use as aromatase inhibitors
US4814333A (en) 1987-07-28 1989-03-21 The Trustees Of Dartmouth College Method for treatment of hypercortisolemic, depressed patients
US5503843A (en) 1994-04-22 1996-04-02 Flora Inc. Transdermal delivery of alpha adrenoceptor blocking agents
US5658881A (en) 1994-10-14 1997-08-19 Twk, Inc. Method for topical inhibition of the metabolic activity of cytochrome P450
DE19814087A1 (de) 1998-03-30 1999-10-14 Lohmann Therapie Syst Lts Feuchtigkeitsaktivierbares therapeutisches System
EP1121111B1 (fr) 1998-10-15 2010-02-10 Imperial Innovations Limited Compositions pour traiter la perte de poids
JP4497814B2 (ja) * 2001-02-16 2010-07-07 アベンティス・ファーマスーティカルズ・インコーポレイテツド 新規複素環式尿素誘導体およびドーパミンｄ３受容体リガンドとしてのそれらの使用
TWI263640B (en) 2001-12-19 2006-10-11 Bristol Myers Squibb Co Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
GB0212412D0 (en) * 2002-05-29 2002-07-10 Novartis Ag Combination of organic compounds
JP5138875B2 (ja) 2005-07-19 2013-02-06 株式会社デンソー センサ装置
GT200600381A (es) * 2005-08-25 2007-03-28 Compuestos organicos
AR056888A1 (es) 2005-12-09 2007-10-31 Speedel Experimenta Ag Derivados de heterociclil imidazol
CA2645678A1 (fr) 2006-03-16 2007-09-20 Yeda Research And Development Co. Ltd. Procede et composition pour la protection du tissu neuronal de degats induits par des niveaux eleves de glutamate
RU2008150752A (ru) 2006-05-26 2010-07-10 Новартис АГ (CH) Ингибиторы альдостеронсинтазы и/или 11-гидроксилазы
EP1886695A1 (fr) 2006-06-27 2008-02-13 Speedel Experimenta AG Combinaisons pharmacéutiques avec inhibiteurs de l'aldosterone synthase et antagonistes du recepteur de glucocorticoides où inhibiteurs de la synthese de cortisol où antagonistes du facteur de libération de la corticotropine
US20090264420A1 (en) * 2006-08-25 2009-10-22 Gary Michael Ksander Organic compounds
US8143278B2 (en) * 2006-12-18 2012-03-27 Novartis Ag Organic compounds
EP2095819A1 (fr) * 2008-02-28 2009-09-02 Maastricht University Dérivés de N-benzyle imidazole et leur utilisation comme inhibiteurs de l'aldosterone synthase
AR072297A1 (es) 2008-06-27 2010-08-18 Novartis Ag Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona.
MA33904B1 (fr) * 2010-01-14 2013-01-02 Novartis Ag Utilisation d'un agent de modification d'hormones surrénaliennes
HRP20160178T1 (hr) * 2012-01-17 2016-03-25 Novartis Ag Novi oblici i soli dihidropirolo[1,2-c]imidazolil inhibitora aldosteron sintaze ili aromataze
WO2013153129A1 (fr) * 2012-04-12 2013-10-17 Novartis Ag Combinaison d'analogues de la somatostatine et d'inhibiteurs de la 11-bêta-hydroxylase

Also Published As

Publication number Publication date
HUE041967T2 (hu) 2019-06-28
MX2012008212A (es) 2012-08-03
LT2523731T (lt) 2019-02-11
TR201900515T4 (tr) 2019-02-21
HUS2000018I1 (hu) 2020-07-28
AU2011205290B2 (en) 2014-06-26
JP5602250B2 (ja) 2014-10-08
PH12012501422A1 (en) 2012-10-22
CA2786443C (fr) 2018-12-11
MX354022B (es) 2018-02-08
HRP20190064T1 (hr) 2019-03-08
CY2020018I1 (el) 2020-11-25
RU2598708C2 (ru) 2016-09-27
EP2523731B1 (fr) 2018-10-24
LUC00159I1 (fr) 2020-06-16
NL301043I2 (nl) 2020-07-06
BR112012017458B1 (pt) 2020-10-20
JP2018150326A (ja) 2018-09-27
AU2011205290A1 (en) 2012-08-02
ES2707596T3 (es) 2019-04-04
CN102711916B (zh) 2015-09-02
JP6425688B2 (ja) 2018-11-21
RU2012134510A (ru) 2014-02-20
EP2523731A1 (fr) 2012-11-21
SG182393A1 (en) 2012-08-30
CY1121320T1 (el) 2020-05-29
AU2011205290C1 (en) 2014-11-06
JP2017002063A (ja) 2017-01-05
KR101412206B1 (ko) 2014-06-25
TN2012000352A1 (en) 2014-01-30
ZA201205058B (en) 2014-04-30
CA2786443A1 (fr) 2011-07-21
US20120295888A1 (en) 2012-11-22
DK2523731T3 (en) 2019-02-04
PL2523731T3 (pl) 2019-04-30
JP2015013859A (ja) 2015-01-22
SI2523731T1 (sl) 2019-02-28
LTC2523731I2 (lt) 2022-05-10
JP6181610B2 (ja) 2017-08-16
EP3527208A1 (fr) 2019-08-21
WO2011088188A1 (fr) 2011-07-21
IL220804A0 (en) 2012-08-30
NZ601077A (en) 2014-07-25
PH12012501422B1 (en) 2018-09-12
BR112012017458A2 (pt) 2017-12-19
US8609862B2 (en) 2013-12-17
HUS000508I2 (hu) 2021-03-29
JP2013517280A (ja) 2013-05-16
CN105440038A (zh) 2016-03-30
CN102711916A (zh) 2012-10-03
CY2020018I2 (el) 2020-11-25
US9434754B2 (en) 2016-09-06
LTPA2020512I1 (lt) 2020-07-27
RS58234B1 (sr) 2019-03-29
LUC00159I2 (fr) 2021-07-06
US20140171392A1 (en) 2014-06-19
ME03371B (fr) 2020-01-20
NO2020012I1 (no) 2020-06-09
CL2012001961A1 (es) 2013-03-22
NL301043I1 (nl) 2020-06-17
KR20120116482A (ko) 2012-10-22
PT2523731T (pt) 2019-01-21

Similar Documents

Publication Publication Date Title
MA33904B1 (fr) Utilisation d'un agent de modification d'hormones surrénaliennes
ZA202306748B (en) Glp-1r receptor agonist compound and use thereof
MA32108B1 (fr) Derives d'indazole
MA37958A1 (fr) Pde9i ayant un squelette imidazo pyrazinone
TNSN08337A1 (fr) Piperidinoylpyrrolidines agonistes du recepteur de melanocortine de type 4
MA34342B1 (fr) Dérivés de la pipéridinone en tant qu'inhibiteurs de mdm2 pour le traitement du cancer
MA33923B1 (fr) Dérivés hétéroaromatiques de phénylimidazole en tant qu'inhibiteurs de l'enzyme pde10a
PE20081704A1 (es) Derivados de azacicloalcanos como inhibidores de estearoil-coenzima a delta-9 desaturasa
MA51837B1 (fr) Inhibiteurs de l'arginase et leurs procédés d'utilisation
MA35032B1 (fr) Derives de glycoside et leurs utilisations dans le traitement du diabete
MA33836B1 (fr) Compositions pharmaceutiques contenant des ligands des récepteurs sigma
EA201000024A1 (ru) Новые производные дикарбоновых кислот в качестве агонистов рецептора s1p1
MA32089B1 (fr) Derives de carboxamides azabicycliques, leur preparation et leur application en therapeutique
BR112013028095A2 (pt) inibidores de csf-1r para o tratamento de tumores cerebrais
MA35364B1 (fr) Dérivés hétérocycliques bicycliques pour le traitement d'une hypertension artérielle pulmonaire
EA201071040A1 (ru) Новые производные 1-бензил-3-гидроксиметилиндазола и их применение при лечении заболеваний, обусловленных экспрессией mcp-1, cx3cr1 и p40
RU2014149183A (ru) Проницаемые ингибиторы гликозидазы и их применения
MA33924B1 (fr) Dérivés de 2-arylimidazole en tant qu'inhibiteurs de l'enzyme pde10a
MY163327A (en) Imidazole derivatives as pde10a enzyme inhibitors
MA38012B1 (fr) Dérivés d'éthynyle comme modulateurs de l'activité des récepteurs mglur5
RU2012150501A (ru) Противораковые стероидные лактоны, ненасыщенные в положении 7(8)
MA60154A1 (fr) Inhibiteurs de line-1 pour traiter une maladie
JOP20240217A1 (ar) مشتقات الكوينولين كمُعدِّلات للعضو x2 لمستقبل بروتين g مرتبط بـ mas ومنتجات ذات صلة
MA38410A1 (fr) Composés d'azétidinyloxyphénylpyrrolidine
MA38659B1 (fr) Dérivés éthynyle comme antagonistes du récepteur métabotrope du glutamate